226 related articles for article (PubMed ID: 31600692)
1. BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma.
Wang M; Zhao L; Tong D; Yang L; Zhu H; Li Q; Zhang F
Int Immunopharmacol; 2019 Nov; 76():105921. PubMed ID: 31600692
[TBL] [Abstract][Full Text] [Related]
2. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
3. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
5. Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses.
Remke N; Bisht S; Oberbeck S; Nolting J; Brossart P
Cancer Immunol Immunother; 2021 Jan; 70(1):107-121. PubMed ID: 32651619
[TBL] [Abstract][Full Text] [Related]
6. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma.
Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH
Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
[TBL] [Abstract][Full Text] [Related]
9. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
10. JQ1, a selective inhibitor of BRD4, suppresses retinoblastoma cell growth by inducing cell cycle arrest and apoptosis.
Zhang Y; Duan S; Jang A; Mao L; Liu X; Huang G
Exp Eye Res; 2021 Jan; 202():108304. PubMed ID: 33080301
[TBL] [Abstract][Full Text] [Related]
11. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
12. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Liu X; Wu H; Huang P; Zhang F
J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.
Toniolo PA; Liu S; Yeh JE; Moraes-Vieira PM; Walker SR; Vafaizadeh V; Barbuto JA; Frank DA
J Immunol; 2015 Apr; 194(7):3180-90. PubMed ID: 25725100
[TBL] [Abstract][Full Text] [Related]
14. JQ1: a novel potential therapeutic target.
Shi X; Liu C; Liu B; Chen J; Wu X; Gong W
Pharmazie; 2018 Sep; 73(9):491-493. PubMed ID: 30223929
[TBL] [Abstract][Full Text] [Related]
15. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
Lochrin SE; Price DK; Figg WD
Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
[TBL] [Abstract][Full Text] [Related]
16. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
17. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells.
Sui S; Zhang J; Xu S; Wang Q; Wang P; Pang D
Cell Death Dis; 2019 Apr; 10(5):331. PubMed ID: 30988278
[TBL] [Abstract][Full Text] [Related]
18. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
19. The Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.
He Z; Jing X; Dai X; Bao L; Yang X; Xiong Y; Li M
Front Biosci (Landmark Ed); 2024 Apr; 29(4):158. PubMed ID: 38682206
[TBL] [Abstract][Full Text] [Related]
20. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
Liao S; Maertens O; Cichowski K; Elledge SJ
Genes Dev; 2018 Sep; 32(17-18):1188-1200. PubMed ID: 30135075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
